Pharmacogenomic testing has utility in determining medication efficacy
For children who require a number of medications, pharmacogenomic testing can be an effective way to determine whether standard medication regimens will be effective.
With children who require a number of medications, such as those with chronic conditions, tracking the safety and efficacy of those medications can be important to reduce the risk of adverse drug reactions. Using pharmacogenomic testing could help assess potential responses to drugs. An investigation in JAMA Network Open offers insight into the clinical utility of using such testing.1
Investigators ran the study at The Hospital for Sick Children in Toronto, Ontario, Canada, from January 2017 to September 2020. The pharmacogenomics analyses were run on children who had been categorized into 2 groups: a point-of-care cohort, which included children referred to the consultation clinic for planned therapy with pharmacogenomic targeted drugs, and a preemptive cohort, which included children who got exploratory whole-genome sequencing–guided pharmacogenomic testing for their heart conditions. The analyses looked at the 6 pharmacogenes (CYP2C19, CYP2C9, CYP2D6, CYP3A5, VKORC1, and TPMT) that have established clinical guidelines.
There were 172 children enrolled in the study with 57 in the point-of-care cohort and 115 in the preemptive cohort. For the point-of-care cohort, there was a median of 2 target genes that were investigated per child and CYP2C19 was the most often examined. The genotypes of 21 children in the cohort were found to not be compatible with the standard treatment regimens. In the preemptive cohort, 92 of the 115 children were recommended to receive a nonstandard regimen for drug therapies due to the findings of the 6-gene pharmacogenetic profile.
The investigators concluded that having a profile of the 6 pharmacogenes as well as implementing a pharmacogenomic program has a clinical benefit for children who require certain medication. They also believe that the findings could be of use to the effort to advance the use and understanding of pharmacogenomic data in routine pediatric care.
Reference
1. Cohn I, Manshaei R, Liston E, et al. Assessment of the implementation of pharmacogenomic testing in a pediatric tertiary care setting. JAMA Netw Open. 2021;4(5):e2110446. doi:10.1001/jamanetworkopen.2021.10446
Fluoxetine helps refractory nocturnal enuresis but not for long
March 29th 2023A 12-week study in Egypt of the efficacy of fluoxetine (a selective serotonin reuptake inhibitor) in children with treatment-refractory nocturnal enuresis (NE) found that though the treatment achieved a good initial response, it was not sustainable.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Are some patients predisposed to avascular necrosis after hip surgery?
March 14th 2023Although avascular necrosis (AVN) is believed to be an iatrogenic complication following treatment of developmental dysplasia of the hip, an investigation in China found 2 characteristics associated with the condition: the likelihood of AVN increases with both the grade of dislocation and of underdevelopment of the ossific nucleus.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.
